Literatur: Prasugrel

Als Hinweis auf potentielle weitere Informationsquellen. Kein Anspruch auf Vollständigkeit.

 

Prasugrel

  • 1. American Geriatrics Society 2012 Beers Criteria Update Expert Panel, "American Geriatrics Society Updated Beers Criteria for Potentially Inappropriate Medication Use in Older Adults," J Am Geriatr Soc, 2012, 60(4):616-31. [PubMed 22376048]
  • 2. Anderson JL, Adams CD, Antman EM, et al, "2011 ACCF/AHA Focused Update Incorporated Into the ACC/AHA 2007 Guidelines for the Management of Patients With Unstable Angina/Non-ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines," Circulation, 2011, 123(18):e426-579. [PubMed 21444888]
  • 3. Antman EM, Anbe SC, Alpert JS, et al, “ACC/AHA Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction - Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1999 Guidelines for the Management of Patients With Acute Myocardial Infarction),” Circulation, 2004, 110(5):588-636. [PubMed 15289388]
  • 4. Antman EM, Hand M, Armstrong PW, et al, “2007 Focused Update of the ACC/AHA 2004 Guidelines for the Management of Patients With ST-Elevation Myocardial Infarction. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines,” J Am Coll Cardiol, 2008, 51(2):210-49. [PubMed 18191746]
  • 5. Bell AD, Roussin A, Cartier R, et al, “The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines,” Can J Cardiol, 2011, 27 (Suppl A):1-59. [PubMed 21640290]
  • 6. Brandt JT, Payne CD, Wiviott SD, et al, “A Comparison of Prasugrel and Clopidogrel Loading Doses on Platelet Function: Magnitude of Platelet Inhibition is Related to Active Metabolite Formation,” Am Heart J, 2007, 153(1):66.e9-16. [PubMed 17174640]
  • 7. Floyd JS and Serebruany VL, “Prasugrel as a Potential Cancer Promoter: Review of the Unpublished Data,” Arch Intern Med, 2010, 170(12):1078-80. [PubMed 20585076]
  • 8. Guyatt GH, Akl EA, Crowther M, et al, “Executive Summary: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines,” Chest, 2012, 141(2 Suppl):7-47. [PubMed 22315257]
  • 9. Hall R and Mazer CD, "Antiplatelet Drugs: A Review of Their Pharmacology and Management in the Perioperative Period," Anesth Analg, 2011, 12(2):292-318. [PubMed 21212258]
  • 10. Hillis LD, Smith PK, Anderson JL, et al, “2011 ACCF/AHA Guideline for Coronary Artery Bypass Graft Surgery: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines,” Circulation, 2011, 124(23):2610-42. [PubMed 22064600]
  • 11. Levine GN, Bates ER, Blankenship JC, et al, “2011 ACCF/AHA/SCAI Guideline for Percutaneous Coronary Intervention: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions,” Circulation, 2011, 124(23):e574-651. [PubMed 22064601]
  • 12. Mega JL, Close SL, Wiviott SD, et al, “Cytochrome P450 Genetic Polymorphisms and the Response to Prasugrel: Relationship to Pharmacokinetic, Pharmacodynamic, and Clinical Outcomes,” Circulation, 2009, 119(19):2553-60. [PubMed 19414633]
  • 13. O’Donoghue ML, Braunwald E, Antman EM, et al, “Pharmacodynamic Effect and Clinical Efficacy of Clopidogrel and Prasugrel With or Without a Proton Pump Inhibitor: an Analysis of Two Randomised Trials,” Lancet, 2009, 374(9694):989-97. [PubMed 19726078]
  • 14. Payne CD, Li YG, Brandt JT, et al, “Switching Directly to Prasugrel from Clopidogrel Results in Greater Inhibition of Platelet Aggregation in Aggregation in Aspirin-treated Subjects,” Platelets, 2008, 19(4):275-81. [PubMed 18569863]
  • 15. Serebruany VL, “Mortality in the TRITON Trial: Update from the FDA Prasugrel Action Package,” Am J Cardiol, 2010, 105(9):1356-7
  • 16. Smith SC Jr, Benjamin EJ, Bonow RO, et al, “AHA/ACCF Secondary Prevention and Risk Reduction Therapy for Patients With Coronary and Other Atherosclerotic Vascular Disease: 2011 Update: A Guideline From the American Heart Association and American College of Cardiology Foundation,” Circulation, 2011, 124(22):2458-73. [PubMed 22052934]
  • 17. Wiviott SD, Braunwald E, McCabe CH, et al, “Intensive Oral Antiplatelet Therapy for Reduction of Ischaemic Events Including Stent Thrombosis in Patients With Acute Coronary Syndromes Treated With Percutaneous Coronary Intervention and Stenting in the TRITON-TIMI 38 Trial: A Subanalysis of a Randomised Trial,” Lancet, 2008, 371(9621):1353-63. [PubMed 18377975]
  • 18. Wiviott SD, Braunwald E, McCabe CH, et al, “Prasugrel versus Clopidogrel in Patients With Acute Coronary Syndromes,” N Engl J Med, 2007, 357(20):2001-15. [PubMed 17982182]
  • 19. Wright RS, Anderson JL, Adams CD, et al, "2011 ACCF/AHA Focused Update of the Guidelines for the Management of Patients with Unstable Angina/Non-ST-Elevation Myocardial Infarction (Updating the 2007 Guideline): A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines Developed in Collaboration With the American College of Emergency Physicians, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons," J Am Coll Cardiol, 2011, 57(19):1920-59. [PubMed 21450428]

 

  top |

 

 
© 2018 Prof. Dr. J. Braun